多发性骨髓瘤患者血浆可溶性Fas水平检测及其临床意义

Detection of plasma soluble Fas in patients with multiple myeloma

:目的 探讨多发性骨髓瘤患者血浆可溶性 Fas(s Fas)水平变化及其临床意义。方法 用酶联免疫吸附试验法 (EL ISA)检测 2 8例多发性骨髓瘤患者及 2 5例正常对照血浆 s Fas值 ,并与多发性骨髓瘤患者骨髓涂片中骨髓瘤细胞数作相关分析。同时测定其中 6例多发性骨髓瘤患者化疗前后 s Fas水平。结果 多发性骨髓瘤患者 s Fas水平显著高于正常对照组 [(10 .36± 6 .87)μg/L ,vs(5 .5 8± 2 .78)μg/L ,P<0 .0 1]。其中 6例多发性骨髓瘤患者化疗前 s Fas水平显著高于化疗后完全缓解时 (P<0 .0 1)。此外 ,骨髓涂片中骨髓瘤细胞数高者 (≥ 15 % ) s Fas水平显著高于骨髓瘤细胞数低者 (<15 % ) [(13.86± 7.10 )μg/L ,vs(6 .36± 3.34 )μg/L ,P<0 .0 1]。结论 提示血浆 s

Objective To investigate the association of plasma soluble Fas (sFas) levels with multiple myeloma (MM).Methods The levels of plasma sFas in 28 patients with MM and 25 normal controls were measured by enzyme linked immunosorbent assays (ELISA).sFas levels in 6 cases before and after chemotherapy were observed.Results sFas levels in MM patients were higher than those of normal controls [(10.36±6.87) μg/L vs (5.58±2.78) μg/L, P <0.01].Moreover,plasma sFas levels in 6 untreated MM patients were much higher than those of these patients with complete remission (CR) induced by chemotherapy ( P <0.01).In addition,sFas levels in the patients with high myeloma cells in bone marrow (≥15%) were higher than those of cases with low myeloma cells (<15%) [(13.86±7.10 μg/L vs (6.36±3.34) μg/L, P < 0.01 )].Conclusion Increasing levels of plasma sFas is associated with the development of MM.\;